Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18661822 | 1.00 | OPRD1 (0.47) | OPRD1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3851995 | 0.87 | — | — | |
| SCHEMBL3983864 | 0.77 | OPRD1 (0.43) | OPRD1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12828282 | 0.73 | SIGMAR1 (0.34) | MAPTSIGMAR1 | |
| SCHEMBL6919165 | 0.72 | OPRD1 (0.46) | OPRD1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4598449 | 0.72 | OPRD1 (0.46) | OPRD1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13993922 | 0.72 | MAPT (0.43) | OPRD1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4598452 | 0.72 | OPRD1 (0.46) | OPRD1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24759193 | 0.71 | HTT (0.33) | — | |
| SCHEMBL23716614 | 0.71 | HTT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138228-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1408037-A1 | Novel diarylmethylpiperazine and diarylmethylphenyl compounds with analgesic effect | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-6680321-B1 | 4-((1-PIPERAZINYLMETHYL)-BENZAMIDE DERIVATIVES; HYPOTENSIVE AGENTS; IMMUNOMODULATORS | ASTRAZENECA CANADA, INC. (CA) | 2004-01-20 | — | — | US | disclosed |
| US-6130222-A | Compounds with analgesic effect | ASTRA PHARMA INC. (CA) | 2000-10-10 | — | — | US | disclosed |
| EP-0915855-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138228-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | OPRD1 4/4885MAPT 2353/4885CYP1A2 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.